Filtered By:
Specialty: Endocrinology
Drug: Insulin

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 211 results found since Jan 2013.

Impact of glucose-lowering therapies on risk of stroke in type 2 diabetes.
Abstract Patients with type 2 diabetes (T2D) have an increased risk of stroke compared with people without diabetes. However, the effects of glucose-lowering drugs on risk of ischaemic stroke in T2D have been less extensively investigated than in coronary heart disease. Some evidence, including the UKPDS, has suggested a reduced risk of stroke with metformin, although the number of studies is limited. Inhibition of the KATP channels increases ischaemic brain lesions in animals. This is in agreement with a recent meta-analysis showing an increased risk of stroke with sulphonylureas vs. various comparators as both m...
Source: Diabetes and Metabolism - May 15, 2017 Category: Endocrinology Authors: Bonnet F, Scheen AJ Tags: Diabetes Metab Source Type: research

Relationship of the metabolic score for insulin resistance and the risk of stroke in patients with hypertension: A cohort study
ConclusionsThis cohort study suggests a relationship between METS-IR and the risk of stroke and ischemic stroke. Further studies are required to elucidate the underlying mechanisms.
Source: Frontiers in Endocrinology - December 5, 2022 Category: Endocrinology Source Type: research

Chromium supplementation improved post-stroke brain infarction and hyperglycemia.
In this study, we investigated whether post-stroke hyperglycemia involved chromium dynamic mobilization in a rat model of permanent focal cerebral ischemia and whether dietary supplement of chromium improved post-stroke injury and alterations. Stroke rats developed brain infarction, hyperglycemia, hyperinsulinemia, glucose intolerance, and insulin resistance. Post-stroke hyperglycemia was accompanied by elevated secretion of counter-regulatory hormones including glucagon, corticosterone, and norepinephrine, decreased insulin signaling in skeletal muscles, and increased hepatic gluconeogenesis. Correlation studies revealed ...
Source: Diabetes Metab - October 19, 2015 Category: Endocrinology Authors: Chen WY, Mao FC, Liu CH, Kuan YH, Lai NW, Wu CC, Chen CJ Tags: Metab Brain Dis Source Type: research

The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial
Publication date: Available online 7 January 2020Source: The Lancet Diabetes & EndocrinologyAuthor(s): Hertzel C Gerstein, Robert Hart, Helen M Colhoun, Rafael Diaz, Mark Lakshmanan, Fady T Botros, Jeffrey Probstfield, Matthew C Riddle, Lars Rydén, Charles Messan Atisso, Leanne Dyal, Stephanie Hall, Alvaro Avezum, Jan Basile, Ignacio Conget, William C Cushman, Nicolae Hancu, Markolf Hanefeld, Petr Jansky, Matyas KeltaiSummaryBackgroundCardiovascular outcome trials have suggested that glucagon-like peptide 1 (GLP-1) receptor agonists might reduce strokes. We analysed the effect of dulaglutide on stroke within the researchi...
Source: The Lancet Diabetes and Endocrinology - January 9, 2020 Category: Endocrinology Source Type: research

Elevated triglyceride-glucose index predicts risk of incident ischaemic stroke: The Rural Chinese Cohort Study
CONCLUSION: Elevated TyG index is an independent predictor of ischaemic stroke in the general population, and insulin resistance may be positively associated with future stroke risk.PMID:33722769 | DOI:10.1016/j.diabet.2021.101246
Source: Diabetes and Metabolism - March 16, 2021 Category: Endocrinology Authors: Yang Zhao Haohang Sun Weidong Zhang Yuanlin Xi Xuezhong Shi Yongli Yang Lu Jie Ming Zhang Liang Sun Hu Dongsheng Source Type: research

GLP-1R activation for the treatment of stroke: Updating and future perspectives.
Abstract Stroke is the leading cause of adult disability in Westernized societies with increased incidence along ageing and it represents a major health and economical threat. Inactive lifestyle, smoking, hypertension, atherosclerosis, obesity and diabetes all dramatically increase the risk of stroke. While preventive strategies based on lifestyle changes and risk factor management can delay or decrease the likelihood of having a stroke, post stroke pharmacological strategies aimed at minimizing stroke-induced brain damage are highly needed. Unfortunately, several candidate drugs that have shown significant precli...
Source: ENDOCR REV - April 30, 2014 Category: Endocrinology Authors: Darsalia V, Nathanson D, Nyström T, Klein T, Sjöholm A, Patrone C Tags: Rev Endocr Metab Disord Source Type: research

Stroke risk in treatment of type 2 diabetes in China: a 7 year retrospective cohort study
Publication date: November 2016 Source:The Lancet Diabetes & Endocrinology, Volume 4, Supplement 1 Author(s): Rui Liu, Qing Wang, Vivian Szeto, Andrew Barszczyk, Tianru Jin, Edoardo Mannucci, Hong-Shuo Sun, Zhong-Ping Feng Background Diabetes and stroke are leading causes of death and disability, and major public health concerns in China, which accounts for 25% of patients with diabetes worldwide. Type 2 diabetes is an independent risk factor for cerebral ischaemia and accounts for about 20% of stroke cases. We previously showed that KATP channel activation provides neuroprotection against cerebral ischaemia and t...
Source: The Lancet Diabetes and Endocrinology - November 17, 2016 Category: Endocrinology Source Type: research

Association of glucose-lowering drugs with incident stroke and transient ischaemic attacks in primary care patients with type 2 diabetes: disease analyzer database
ConclusionsTreatment with SGLT2 inhibitors or GLP-1 receptor agonists might reduce non-fatal stroke/TIA in persons with newly diagnosed type 2 diabetes.
Source: Acta Diabetologica - August 6, 2022 Category: Endocrinology Source Type: research

Elevated stress hyperglycemia and the presence of intracranial artery stenosis increase the risk of recurrent stroke
ConclusionsSHR represents a better biomarker to predict the risk of stroke recurrence in patients with ICAS than FPG and HbA1c regardless of previous diabetes mellitus.Trial registrationhttps://www.chictr.org.cn/showproj.aspx?proj=125817; Identifier, [ChiCTR2100046958].
Source: Frontiers in Endocrinology - January 9, 2023 Category: Endocrinology Source Type: research

GLP-1R activation for the treatment of stroke: Updating and future perspectives
Abstract Stroke is the leading cause of adult disability in Westernized societies with increased incidence along ageing and it represents a major health and economical threat. Inactive lifestyle, smoking, hypertension, atherosclerosis, obesity and diabetes all dramatically increase the risk of stroke. While preventive strategies based on lifestyle changes and risk factor management can delay or decrease the likelihood of having a stroke, post stroke pharmacological strategies aimed at minimizing stroke-induced brain damage are highly needed. Unfortunately, several candidate drugs that have shown significant precl...
Source: Reviews in Endocrine and Metabolic Disorders - September 1, 2014 Category: Endocrinology Source Type: research

Is management of hyperglycaemia in acute phase stroke still a dilemma?
ConclusionBoth hypoglycaemia and hyperglycaemia may lead to further brain injury and clinical deterioration; that is the reason these conditions should be avoided after stroke. Yet, when correcting hyperglycaemia, great care should be taken not to switch the patient into hypoglycaemia, and subsequently aggressive insulin administration treatment should be avoided. Early identification and prompt management of hyperglycaemia, especially in acute ischaemic stroke, is recommended. Although the appropriate level of blood glucose during acute stroke is still debated, a reasonable approach is to keep the patient in a mildly hype...
Source: Journal of Endocrinological Investigation - November 20, 2016 Category: Endocrinology Source Type: research

Association Between Levels of Serum Insulin-like Growth Factor I and Functional Recovery, Mortality, and Recurrent Stroke at a 7-year Follow-up
Conclusion The association for s-IGF-I with long-term post-stroke recovery persists after 7 years, which is also reflected in the mRS score distributions at all time-points. The effects are however modest, and not driven by mortality or recurrent stroke. [...] © Georg Thieme Verlag KG Stuttgart · New YorkArticle in Thieme eJournals: Table of contents  |  Abstract  |  open access Full text
Source: Experimental and Clinical Endocrinology and Diabetes - June 30, 2019 Category: Endocrinology Authors: Åberg, N. David Åberg, Daniel Lagging, Cecilia Holmegaard, Lukas Redfors, Petra Jood, Katarina Nilsson, Michael Åberg, Maria Blomstrand, Christian Svensson, Johan Jern, Christina Isgaard, J örgen Tags: Article Source Type: research

Glycemic Control in Hospitalized Stroke Patients: A Review
AbstractPurpose of ReviewThe purpose of this review is to discuss clinical trials involving glycemic control in hospitalized stroke patients and to review oral medications used in glycemic control. GLP-1 agonists, which have some preliminary studies in ischemic stroke, will also be reviewed.Recent FindingsUntil recently, glycemic control targets in hospitalized stroke patients remained unclear. The SHINE (Stroke Hyperglycemia Insulin Network Effort) trial demonstrated no significant difference between aggressive versus standard of care glycemic control in the acute ischemic stroke patient.SummaryAlthough SHINE demonstrated...
Source: Current Diabetes Reports - December 1, 2021 Category: Endocrinology Source Type: research

Activation of hepatic inflammatory pathways by catecholamines is associated with hepatic insulin resistance in male ischemic stroke rats.
Abstract Patients who experience acute ischemic stroke may develop hyperglycemia, even in the absence of diabetes. In the current study we determined the effects of acute stroke on hepatic insulin signaling, tumor necrosis factor α (TNF-α) expression, endoplasmic reticulum (ER) stress, the activities of c-Jun N-terminal kinase (JNK), inhibitor κB kinase β (IKK-β), and nuclear factor-κB (NF-κB) pathways. Rats with cerebral ischemia developed higher blood glucose, and insulin levels, and insulin resistance index, as well as hepatic gluconeogenic enzyme expression compared to the sham-treated group. The hepati...
Source: Endocrinology - January 17, 2014 Category: Endocrinology Authors: Wang YY, Lin SY, Chuang YH, Sheu WH, Tung KC, Chen CJ Tags: Endocrinology Source Type: research